Dexmedetomidine-induced cerebral hypoperfusion exacerbates ischemic brain injury in rats

Journal of Anesthesia

Volumn 23, Issue 3, 2009, Pages 378-384

  Nakano, Takaaki ^a   Okamoto, Hirotsugu ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Alpha 2 adrenoceptor; Cerebral blood flow; Dexmedetomidine; Middle cerebral artery occlusion; Yohimbine

Indexed keywords

DEXMEDETOMIDINE; RAUWOLSCINE; SODIUM CHLORIDE; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; BRAIN PERFUSION; BRAIN SIZE; BRAIN VASCULAR RESISTANCE; CONTROLLED STUDY; DRUG DOSE INCREASE; MALE; MEAN ARTERIAL PRESSURE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; RAT; TOXICITY TESTING; VASOCONSTRICTION;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BLOOD PRESSURE; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; DEXMEDETOMIDINE; HYPNOTICS AND SEDATIVES; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; VASCULAR RESISTANCE; YOHIMBINE;

EID: 69049085752     PISSN: 09138668     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00540-009-0777-9     Document Type: Article

References (37)

1. Tobias JD. Dexmedetomidine to treat opioid withdrawal in infants following prolonged sedation in the pediatric ICU. J Opioid Manag. 2006;2:201-205.
2. Hammer GB, Philip BM, Schroeder AR, Rosen FS, Koltai PJ. Prolonged infusion of dexmedetomidine for sedation following tracheal resection. Paediatr Anaesth. 2005;15:616-620.
3. Chrysostomou C, Zeballos T. Use of dexmedetomidine in a pediatric heart transplant patient. Pediatr Cardiol. 2005;26:651-654.
4. Chrysostomou C, Di Filippo S, Manrique AM, et al. Use of dexmedetomidine in children after cardiac and thoracic surgery. Pediatr Crit Care Med. 2006;7:126-131.
5. Civantors Calazda B, Aleixandre de Artinano A. Alpha adrenoceptor subtypes. Pharmacol Res. 2001;44:195-208.
6. Hoffman WE, Kochs E, Werner C, Thomas C, Albrecht RF: Dexmedetomidine improves neurologic outcome from incomplete ischemia in the rat. Anesthesiology. 1991;75:328-332.
7. Ma D, Hossain M, Rajakumaraswamy N, Arshad M, Sanders RD, Franks NP, Maze M. Dexmedetomidine produces its neuroprotective effect via the alpha 2A-adrenoceptor subtype. Eur J Pharmacol. 2004;502:87-97.
8. Jolkkonen J, Puurunen K, Koistinaho J, Kauppinen R, Haapalinna A, Nieminen L, Sivenius J. Neuroprotection by the alpha2-adrenoceptor agonist, dexmedetomidine, in rat focal cerebral ischemia. Eur J Pharmacol. 1999;372:31-36.
9. Paris A, Mantz J, Tonner PH, Hein L, Brede M, Gressens P. The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype. Anesth Analg. 2006;102:456-461.
10. Talke P, Lobo E, Brown R. Systemically administered alpha2-agonist-induced peripheral vasoconstriction in humans. Anesthesiology. 2003;99:65-70.
11. Prielipp RC, Wall MH, Tobin JR, Groban L, Cannon MA, Fahey FH, Gage HD, Stump DA, James RL, Bennett J, Butterworth J. Dexmedetomidine-induced sedation in volunteers decreases regional and global cerebral blood flow. Anesth Analg. 2002; 95:1052-1059.
12. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93:382-394.
13. Link RE, Desai K, Hein L, Stevens ME, Chruscinski A, Bernstein D, Barsh GS, Kobilka BK. Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c. Science. 1996;273:803-805.
14. Quan N, Xin L, Ungar AL, Blatteis CM. Preoptic norepinephrine-induced hypothermia is mediated by alpha 2-adrenoceptors. Am J Physiol. 1992;262(3 Pt 2):R407-R411.
15. Haapalinna A, Leino T, Heinonen E. The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats. Naunyn Schmiedebergs Arch Pharmacol. 2003;368:342-351. Epub 2003 Oct 18.
16. Viitamaa T, Haapalinna A, Agmo A. The adrenergic alpha2 receptor and sexual incentive motivation in male rats. Pharmacol Biochem Behav. 2006;83:360-369. Epub 2006 Mar 6.
17. Billings FT 4th, Chen SW, Kim M, Park SW, Song JH, Wang S, Herman J, D'Agati V, Lee HT. Alpha2-adrenergic agonists protect against radiocontrast-induced nephropathy in mice. Am J Physiol Renal Physiol. 2008;295:F741-F748. Epub 2008 Jun 25.
18. Rusa R, Alkayed NJ, Crain BJ, Traystman RJ, Kimes AS, London ED, Klaus JA, Hurn PD. 17Beta-estradiol reduces stroke injury in estrogen-deficient female animals. Stroke. 1999;30:1665-1670.
19. Engelhard K, Werner C, Eberspächer E, Bachl M, Blobner M, Hildt E, Hutzler P, Kochs E. The effect of the alpha 2-agonist dexmedetomidine and the N-methyl-D-aspartate antagonist S(+)-ketamine on the expression of apoptosis-regulating proteins after incomplete cerebral ischemia and reperfusion in rats. Anesth Analg. 2003;96:524-531.
20. Dettmers C, Hartmann A, Rommel T, Krämer S, Pappata S, Young A, Hartmann S, Ziert S, MacKenzie ET, Baron JC. Immersion and perfusion staining with 2, 3, 5-triphenyltetrazolium chloride (TTC) compared to mitochondrial enzymes 6 hours after MCA-occlusion in primates. Neurol Res. 1994;16:205-208.
21. Hatfield RH, Mendelow AD, Perry RH, Alvarez LM, Modha P. Triphenyltetrazolium chloride (TTC) as a marker for ischaemic changes in rat brain following permanent middle cerebral artery occlusion. Neuropathol Appl Neurobiol. 1991;17:61-67.
22. Okuno S, Nakase H, Sakaki T. Comparative study of 2, 3, 5-triphenyltetrazolium chloride (TTC) and hematoxylin-eosin staining for quantification of early brain ischemic injury in cats. Neurol Res. 2001;23:657-661.
23. Tureyen K, Vemuganti R, Sailor KA, Dempsey RJ. Infarct volume quantification in mouse focal cerebral ischemia: A comparison of triphenyltetrazolium chloride and cresyl violet staining techniques. J Neurosci Methods. 2004;139:203-207.
24. Zornow MH, Scheller MS, Sheehan PB, Strant MAP, Matsumoto M. Intracranial pressure effects of dexmedetomidine in rabbits. Anesth Analg. 1992;75:232-237.
25. Karlsson BR, Forsman M, Roald OK, Heier MS, Steen PA. Effect of dexmedetomidine, a selective and potent α2-agonist, on cerebral blood flow and oxygen consumption during halothane anesthesia in dogs. Anesth Analg. 1990;71:125-129.
26. Prielipp RC, Wall MH, Tobin JR, Groban L, Cannon MA, Fahey FH, Gage HD, Stump DA, James RL, Bennett J, Butterworth J. Dexmedetomidine induced sedation in volunteers decreases regional and global cerebral blood flow. Anesth Analg. 2002;95:1052-1059.
27. Aryan HE, Box KW, Ibrahim D, Desiraju U, Ames CP. Safety and efficacy of dexmedetomidine in neurosurgical patients. Brain Inj. 2006;20:791-798.
28. Talke P, Richardson CA, Scheinin M, Fisher DM. Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. Anesth Analg. 1997;85:1136-1142.
29. Erkonen G, Lamb F, Tobias JD. High-dose dexmedetomidineinduced hypertension in a child with traumatic brain injury. Neurocrit Care. 2008;9:366-369.
30. Mason KP, Zgleszewski SE, Prescilla R, Fontaine PJ, Zurakowski D. Hemodynamic effects of dexmedetomidine sedation for CT imaging studies. Paediatr Anaesth. 2008;18:393-402. Epub 2008 Mar 18.
31. MacMillan LB, Hein L, Smith MS, Piascik MT, Limbird LE. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science. 1996;273:801-803.
32. Kurnik D, Muszkat M, Sofowora GG, Friedman EA, Dupont WD, Scheinin M, Wood AJ, Stein CM. Ethnic and genetic determinants of cardiovascular response to the selective alpha 2-adrenoceptor agonist dexmedetomidine. Hypertension. 2008;51:406-411. Epub 2007 Dec 10.
33. Kanagy NL. Alpha (2)-adrenergic receptor signalling in hypertension. Clin Sci (Lond). 2005;109:431-437.
34. Zhang Y. Clonidine preconditioning decreases infarct size and improves neurological outcome from transient forebrain ischemia in the rat. Neuroscience. 2004;125:625-631.
35. Halonen T, Kotti T, Tuunanen J, Toppinen A, Miettinen R, Riekkinen PJ. Alpha 2-adrenoceptor agonist, dexmedetomidine, protects against kainic acid-induced convulsions and neuronal damage. Brain Res. 1995;693:217-224.
36. Kuhmonen J, Pokorný J, Miettinen R, Haapalinna A, Jolkkonen J, Riekkinen P Sr, Sivenius J. Neuroprotective effects of dexmedetomidine in the gerbil hippocampus after transient global ischemia. Anesthesiology. 1997;87:371-377.
37. Drummond JC, Dao AV, Roth DM, Cheng CR, Atwater BI, Minokadeh A, Pasco LC, Patel PM. Effect of dexmedetomidine on cerebral blood flow velocity, cerebral metabolic rate, and carbon dioxide response in normal humans. Anesthesiology. 2008;108:225-232.